Research Question: Can Alphatec’s product development program and strategic distributor sales channel initiatives deliver sustained double-digit growth? Companies: ATEC, GMED, JNJ, MDT, NUVA, SPNE, SYK, ZBH By: David Franklin Click here to download report (.pdf) Summary of Findings Alphatec Holdings Inc.’s (ATEC) product development program and its sales channel changes generated mixed opinions regarding […]
Can Alphatec’s product development program and strategic distributor sales channel initiatives deliver sustained double-digit growth? Report Available: January 7, 2021 Blueshift’s initial research found ATEC transformed by a new leadership team, shedding its past legacy of lacking distinction to one providing innovative spine surgery solutions. The company is now promoting clinical excellence by introducing […]
Research Question: Can Inspire execute on its commercial expansion initiative to accelerate growth or is its implantable therapy a niche treatment? Companies: INSP, LIVN, NYXH By: David Franklin Click here to download report (.pdf) Summary of Findings Inspire Medical Systems Inc.’s (INSP) minimally invasive hypoglossal nerve stimulation device for the treatment of moderate to […]
Can Inspire execute on its commercial expansion initiative to accelerate growth or is its implantable therapy a niche treatment? Report Available: December 10, 2020 Blueshift’s initial research found INSP working to accelerate the use and adoption of its Inspire system for the treatment of obstructive sleep apnea (OSA). Direct-to-consumer advertising, increased physician outreach and […]
Research Question: Will Neuronetics’ C-suite changes, new treatment indication, expanded reimbursement, and new positive data reinvigorate growth? Companies: BWAY, GTMS, NXTMH.HE, STIM By: David Franklin Click here to download report (.pdf) Summary of Findings Neuronetics Inc.‘s (STIM) business model, requiring psychiatric practices and TMS (transcranial magnetic stimulation) clinics to spend significant sums to acquire […]
Will Neuronetics’ C-suite changes, new treatment indication, expanded reimbursement, and new positive data reinvigorate growth? Report Available: November 4, 2020 Blueshift’s initial research found STIM, a leader in providing transcranial magnetic stimulation (TMS) therapy equipment and support for the treatment of Major Depressive Disorder (MDD), navigating through the coronavirus, which has had a significant […]
Research Question: Is the stronger-than-expected second-quarter demand Axogen experienced for its nerve regeneration products sustainable? Companies: ABBV, AXGN, HSIC, IART, SYK By: David Franklin Click here to download report (.pdf) Summary of Findings Sources were mixed trending positive regarding Axogen Inc.’s (AXGN) ability to sustain the stronger-than-expected Q2 demand for its nerve repair and […]
Is the stronger-than-expected Q2 demand Axogen experienced for its nerve regeneration products sustainable? Report Available: October 8, 2020 Blueshift’s initial research found AXGN, the leader in the development and commercialization of technologies for peripheral nerve regeneration and repair, experiencing a strong rebound in growth following the late Q1 and early Q2 2020 sales declines […]
Research Question: As the continuous glucose monitoring market continues to innovate, integrate, and grow, are insulin pump makers Tandem, Insulet, and Medtronic poised to follow? Companies: ABT, DXCM, MDT, PODD, SENS, TNDM By: David Franklin Click here to download report (.pdf) Summary of Findings The continuous glucose monitoring (CGM) and insulin pump markets are […]
As the continuous glucose monitoring market continues to innovate, integrate, and grow, are insulin pump makers Tandem, Insulet, and Medtronic poised to follow? Report Available: September 3, 2020 Blueshift’s initial research found the continues glucose monitoring (CGM) market experiencing increasing demand from both Type 1 and Type 2 diabetics. The CGM space has also […]
Copyright © 2015 Blueshift Research, LLC. All rights reserved.